{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T05:15:21Z","timestamp":1773724521007,"version":"3.50.1"},"reference-count":19,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2013,10,22]],"date-time":"2013-10-22T00:00:00Z","timestamp":1382400000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Pfizer Inc","award":["Na"],"award-info":[{"award-number":["Na"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2014,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:label\/><jats:p>In order to evaluate the potential for CYP3A4 induction by moxidectin, midazolam pharmacokinetic (PK) parameters were compared before and after moxidectin administration. Healthy subjects received a single 8\u2009mg dose of moxidectin and 3 single 7.5\u2009mg doses of midazolam 3 days before, and 7 and 89 days after the moxidectin. Blood samples were taken for 24\u2009hours to measure midazolam and metabolites in plasma, and for 89 days to measure moxidectin in plasma after dose administration. Noncompartmental PK analyses were performed for each analyte. Analysis of variance was performed on log\u2010transformed midazolam parameters with treatment day as a fixed effect. Adverse events were recorded and laboratory tests, physical examinations, pulse oximetry monitoring, vital sign measurement, and electrocardiograms performed. Thirty\u2010nine subjects were enrolled in the study; PK data were available for 37 subjects. Moxidectin PK parameters were similar to previous studies. There were no significant changes in PK for midazolam or its metabolites 7 or 89 days after moxidectin administration. Adverse events were generally mild and there were no relevant changes in safety assessments. Thus, 8\u2009mg moxidectin does not induce CYP3A4 activity and other CYP3A4 substrates are unlikely to be affected by moxidectin co\u2010administration.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cpdd.81","type":"journal-article","created":{"date-parts":[[2013,10,11]],"date-time":"2013-10-11T23:37:06Z","timestamp":1381534626000},"page":"151-157","source":"Crossref","is-referenced-by-count":22,"title":["Effect of moxidectin on CYP3A4 activity as evaluated by oral midazolam pharmacokinetics in healthy subjects"],"prefix":"10.1002","volume":"3","author":[{"given":"Joan M.","family":"Korth\u2010Bradley","sequence":"first","affiliation":[{"name":"Pfizer, Inc. Collegeville PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Virginia","family":"Parks","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Wagner","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Research Organisation GmbH Berlin Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephan","family":"Chalon","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Gourley","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. Collegeville PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyle","family":"Matschke","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. Collegeville PA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Gossart","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. Paris France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sharon L.","family":"Ripp","sequence":"additional","affiliation":[{"name":"Pfizer, Inc. Groton CT USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Fleckenstein","sequence":"additional","affiliation":[{"name":"College of Pharmacy University of Iowa Iowa City IA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,10,22]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"APOC. Final Communique: Eleventh session of the Joint Action Forum. 2005.http:\/\/www.who.int\/apoc\/about\/structure\/jaf\/en\/index.htmlAccessed June 24 2013."},{"key":"e_1_2_6_3_1","unstructured":"World Health Organization. Working to overcome the global impact of neglected tropical diseases: update to WHO report on neglected tropical diseases. 2011.http:\/\/www.who.int\/neglected_diseases\/2010report\/WHO_NTD_report_update_2011.pdfAccessed June 24 2013."},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.1999.0433"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003257456"},{"key":"e_1_2_6_6_1","unstructured":"World Health Organization. Study comparing moxidectin and ivermectin in subjects withOnchocerca volvulusinfection. 2011.http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00790998Accessed June 24 2013."},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/2160763X11432508"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.4269\/ajtmh.2012.11-0415"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.0306-5251.2001.temp.1441.x"},{"key":"e_1_2_6_10_1","unstructured":"European Medicines Agency. Guideline on the investigation of drug interactions 2012.http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdfAccessed June 24 2013."},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270003259216"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0731-7085(02)00120-6"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.4172\/jbb.1000134"},{"key":"e_1_2_6_14_1","unstructured":"US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research (CDER) Guidance for Industry Drug Interaction Studies \u2013 Study Design Data Analysis Implications for Dosing and Labeling Recommendations 2012.http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm292362.pdfAccessed June 24 2013."},{"key":"e_1_2_6_15_1","unstructured":"World Health Organization. African Programme for Onchocerciasis Control (APOC): Treatment and control of onchocerciasis.http:\/\/www.who.int\/apoc\/onchocerciasis\/control\/en\/Accessed June 24 2013."},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00311-11"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1989.tb03327.x"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.2174\/138920307783018668"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2005.11.016"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0009-9236(96)90018-1"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcpdd.81","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.81","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T16:24:12Z","timestamp":1696609452000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.81"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10,22]]},"references-count":19,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1002\/cpdd.81"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.81","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,10,22]]}}}